s6y

20-F Annual and transition report of foreign private issuers pursuant to Section 13 or 15(d)

Filed
Period
Accession number
0001213900-26-050282

Documents

  1. ANNUAL REPORT 20-F
  2. DESCRIPTION OF SECURITIES EX-2.1
  3. BINDING LETTER OF INTENT, DATED JANUARY 20, 2026, BY AND BETWEEN YD BIO LIMITED AND SAFE SAVE MEDICAL CELL SCIENCES & TECHNOLOGY CO., LTD EX-4.15
  4. MASTER STRATEGIC ALLIANCE AGREEMENT, DATED FEBRUARY 24, 2026, BY AND BETWEEN YD BIO USA, INC. AND YC BIOTECH CO., LTD EX-4.16
  5. LIST OF SUBSIDIARIES EX-8.1
  6. CODE OF ETHICS EX-11.1
  7. INSIDER TRADING POLICY EX-11.2
  8. CERTIFICATION EX-12.1
  9. CERTIFICATION EX-12.2
  10. CERTIFICATION EX-13.1
  11. CERTIFICATION EX-13.2
  12. CONSENT OF MALONEBAILEY LLP, INDEPENDENT REGISTERED PUBLIC ACCOUNTING FIRM FOR YD BIO LIMITED EX-15.1
  13. CONSENT OF ARK PRO CPA & CO., INDEPENDENT REGISTERED PUBLIC ACCOUNTING FIRM EX-15.2
  14. LETTER OF MARCUM LLP, DATED APRIL 30, 2026 EX-16.1
  15. LETTER OF ARK PRO CPA & CO., DATED APRIL 30, 2026 EX-16.3
  16. COMPENSATION RECOVERY POLICY EX-97.1
  17. XBRL SCHEMA FILE EX-101.SCH
  18. XBRL CALCULATION FILE EX-101.CAL
  19. XBRL DEFINITION FILE EX-101.DEF
  20. XBRL LABEL FILE EX-101.LAB
  21. XBRL PRESENTATION FILE EX-101.PRE

On sec.gov